CN114984126A - Biological agent suitable for supplementing hormone for female and production method thereof - Google Patents
Biological agent suitable for supplementing hormone for female and production method thereof Download PDFInfo
- Publication number
- CN114984126A CN114984126A CN202210829405.0A CN202210829405A CN114984126A CN 114984126 A CN114984126 A CN 114984126A CN 202210829405 A CN202210829405 A CN 202210829405A CN 114984126 A CN114984126 A CN 114984126A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- prepared
- stirring
- arctigenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a biological medicament suitable for supplementing hormones for women and a production method thereof, and the formula comprises the following components: pregnant mare urine extract, soybean isoflavone powder, larch resin alcohol powder, matairesinol powder, arctigenin powder, resveratrol glycoside powder, defatted coconut powder, purified water, polyglutamic acid, citric acid, calcium lactate, tween, sorbitan trioleate and seaweed gel; the method comprises the following steps: step one, preparing materials; step two, stirring; step three, dissolving; step four, evaporating; step five, granulation; step six, tabletting; the invention contains various phytoestrogens, has more functional components, good hormone supplementing effect, small side effect, less adverse reaction and strong applicability, takes biomass as a main component, has strong solubility, high degradation rate and less substance residue, ensures the health of women, increases the dehydration strength during production by rotary evaporation, has less residual water in the medicament, ensures the absorption of the functional components and has reliable curative effect.
Description
Technical Field
The invention relates to the technical field of biological agents, in particular to a biological agent suitable for supplementing hormones for women and a production method thereof.
Background
Female hormones are the collective term for estrogen and lutein. At present, the medicines for clinically helping women to supplement hormones mainly comprise estradiol, ethinylestradiol, diethylstilbestrol, progesterone, tibolone, raloxifene, medroxyprogesterone, chorionic gonadotropin, clomiphene and leuprorelin chemical agents. However, the existing chemical agents have the defects of single functional components, poor hormone supplementing effect, large side effect, more adverse reactions, poor applicability, poor solubility, low degradation rate, certain substance residues, harm to the health of women after long-term use, insufficient dehydration strength during production, more residual moisture in the agents, influence on the absorption of the functional components and limited curative effect.
Disclosure of Invention
The present invention aims at providing one kind of female hormone replenishing biological medicine and its production process to solve the problems of the background technology.
In order to achieve the purpose, the invention provides the following technical scheme: a biological agent suitable for supplementing hormone for female comprises: pregnant mare urine extract, soybean isoflavone powder, larch resin alcohol powder, matairesinol powder, arctigenin powder, resveratrol glycoside powder, defatted coconut powder, purified water, polyglutamic acid, citric acid, calcium lactate, tween, sorbitan trioleate and seaweed gel; the weight parts of the components are respectively as follows: 26-40 parts of pregnant mare urine extract, 10-14 parts of soybean isoflavone powder, 8-12 parts of larch resin alcohol powder, 8-12 parts of matairesinol powder, 3-5 parts of arctigenin powder, 3-5 parts of resveratrol glycoside powder, 70-76 parts of defatted coconut powder, 41-47 parts of purified water, 23-27 parts of polyglutamic acid, 7-11 parts of citric acid, 4-6 parts of calcium lactate, 10-12 parts of tween, 1-3 parts of sorbitan trioleate and 5-9 parts of seaweed gel.
A method for producing a biological agent suitable for supplementing hormones to women, comprising the steps of: step one, preparing materials; step two, stirring; step three, dissolving; step four, evaporation; step five, granulation; step six, tabletting;
in the first step, 26-40 parts of pregnant mare urine extract, 10-14 parts of soybean isoflavone powder, 8-12 parts of larch resin alcohol powder, 8-12 parts of matairesinol powder, 3-5 parts of arctigenin powder, 3-5 parts of resveratrol glycoside powder, 70-76 parts of defatted coconut powder, 41-47 parts of purified water, 23-27 parts of polyglutamic acid, 7-11 parts of citric acid, 4-6 parts of calcium lactate, 10-12 parts of tween, 1-3 parts of sorbitan trioleate and 5-9 parts of seaweed gel are weighed according to the parts by weight of the components for later use;
pouring the pregnant mare urine extract prepared in the step one into a dry powder stirrer, adding the soybean isoflavone powder, the larch resin alcohol powder, the matairesinol powder, the arctigenin powder and the resveratrol glycoside powder prepared in the step one, and stirring and mixing uniformly to obtain medicinal powder;
pouring the purified water prepared in the step one into a magnetic stirrer, adding the medicinal powder obtained in the step two, heating, stirring and mixing uniformly, adding the polyglutamic acid, citric acid and calcium lactate prepared in the step one, heating, stirring and mixing uniformly to obtain a liquid medicine;
pouring the liquid medicine obtained in the third step into a rotary evaporator, adding the Tween, sorbitan trioleate and seaweed gel prepared in the first step, heating, rotating at a high speed, and evaporating and discharging redundant water to obtain liquid medicine;
pouring the medicine slurry obtained in the fourth step into a granulator, and obtaining medicine granules after extrusion, rounding and drying;
and in the sixth step, the medicine granules obtained in the fifth step are poured into a tablet machine, the defatted coconut powder prepared in the first step is added, the mixture is pressed into tablets after mixing, tablet cores are obtained, then the tablets are transferred into a film coating machine, the surfaces of the tablet cores are coated with the prepared coating materials, and the tablets are taken out after being solidified into films, so that the biological medicine is obtained.
Preferably, in the second step, the stirring speed of the dry powder stirrer is 240-320 r/min, and the stirring time is 7-11 min.
Preferably, in the third step, the heating temperature of the magnetic stirrer is 85-90 ℃, and the stirring speed is 80-120 r/min.
Preferably, in the fourth step, the heating temperature of the rotary evaporator is 98-103 ℃, and the rotating speed is 120-150 r/s.
Preferably, in the fifth step, the discharged material of the granulator has a particle size of 45-55 meshes and a water content of 1.6-1.9%.
Compared with the prior art, the invention has the beneficial effects that: the biological agent suitable for supplementing hormones for women and the production method thereof contain various phytoestrogens, have more functional components, good effect of supplementing hormones, small side effect, less adverse reaction and strong applicability; the biological material takes biomass as a main component, has strong solubility, high degradation rate and less substance residue, and ensures the health of women; through rotary evaporation, the dehydration degree during production is increased, the residual water in the medicament is less, the absorption of effective components is ensured, and the curative effect is reliable.
Drawings
FIG. 1 is a flow chart of the method of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Referring to fig. 1, the present invention provides a technical solution:
example 1:
a biological agent suitable for supplementing hormone for female comprises: pregnant mare urine extract, soybean isoflavone powder, larch resin alcohol powder, matairesinol powder, arctigenin powder, resveratrol glycoside powder, defatted coconut powder, purified water, polyglutamic acid, citric acid, calcium lactate, tween, sorbitan trioleate and seaweed gel; the weight parts of the components are respectively as follows: 6 parts of pregnant mare urine extract, 10 parts of soybean isoflavone powder, 8 parts of larch resin alcohol powder, 8 parts of matairesinol powder, 3 parts of arctigenin powder, 3 parts of resveratrol glycoside powder, 70 parts of defatted coconut powder, 41 parts of purified water, 23 parts of polyglutamic acid, 7 parts of citric acid, 4 parts of calcium lactate, 10 parts of tween, 1 part of sorbitan trioleate and 5 parts of seaweed gel.
A method for producing a biological agent suitable for supplementing hormones in women comprises the following steps: step one, preparing materials; step two, stirring; step three, dissolving; step four, evaporation; step five, granulation; step six, tabletting;
in the first step, 6 parts of pregnant mare's urine extract, 10 parts of soybean isoflavone powder, 8 parts of larch resin alcohol powder, 8 parts of palonodulcin powder, 3 parts of arctigenin powder, 3 parts of resveratrol glycoside powder, 70 parts of defatted coconut powder, 41 parts of purified water, 23 parts of polyglutamic acid, 7 parts of citric acid, 4 parts of calcium lactate, 10 parts of tween, 1 part of sorbitan trioleate and 5 parts of seaweed gel are respectively weighed according to the parts by weight of the components for later use;
in the second step, the pregnant mare urine extract prepared in the first step is poured into a dry powder stirrer, and the soybean isoflavone powder, the larch resin alcohol powder, the matairesinol powder, the arctigenin powder and the resveratrol glycoside powder prepared in the first step are added, stirred at 280r/min for 9min and uniformly mixed to obtain medicinal powder;
pouring the purified water prepared in the step one into a magnetic stirrer, adding the medicinal powder obtained in the step two, heating at 87 ℃, stirring and mixing uniformly at 100r/min, adding the polyglutamic acid, the citric acid and the calcium lactate prepared in the step one, heating, stirring and mixing uniformly to obtain a liquid medicine;
in the fourth step, the liquid medicine obtained in the third step is poured into a rotary evaporator, the Tween, the sorbitan trioleate and the seaweed gel prepared in the first step are added, the mixture is heated at 100 ℃ and then rotates at a high speed of 140r/s, and redundant water is evaporated and discharged to obtain medicine slurry;
pouring the medicine slurry obtained in the fourth step into a granulator, and obtaining medicine granules with the discharged particle size of 50 meshes and the discharged water content of 1.8% after extrusion, rounding and drying;
and in the sixth step, the medicine granules obtained in the fifth step are poured into a tablet machine, the defatted coconut powder prepared in the first step is added, the mixture is pressed into tablets after mixing, tablet cores are obtained, then the tablets are transferred into a film coating machine, the surfaces of the tablet cores are coated with the prepared coating materials, and the tablets are taken out after being solidified into films, so that the biological medicine is obtained.
Example 2:
a biological agent suitable for supplementing hormone for female comprises: pregnant mare urine extract, soybean isoflavone powder, larch resin alcohol powder, matairesinol powder, arctigenin powder, resveratrol glycoside powder, defatted coconut powder, purified water, polyglutamic acid, citric acid, calcium lactate, tween, sorbitan trioleate and seaweed gel; the weight parts of the components are respectively as follows: 30 parts of pregnant mare urine extract, 11 parts of soybean isoflavone powder, 9 parts of larch resin alcohol powder, 9 parts of matairesinol powder, 3 parts of arctigenin powder, 4 parts of resveratrol glycoside powder, 12 parts of defatted coconut powder, 42 parts of purified water, 24 parts of polyglutamic acid, 8 parts of citric acid, 4 parts of calcium lactate, 11 parts of tween, 1 part of sorbitan trioleate and 6 parts of seaweed gel.
A method for producing a biological agent suitable for supplementing hormones to women, comprising the steps of: step one, preparing materials; step two, stirring; step three, dissolving; step four, evaporation; step five, granulating; step six, tabletting;
in the first step, 30 parts of pregnant mare urine extract, 11 parts of soybean isoflavone powder, 9 parts of larch resin alcohol powder, 9 parts of matairesinol powder, 3 parts of arctigenin powder, 4 parts of resveratrol glycoside powder, 12 parts of defatted coconut powder, 42 parts of purified water, 24 parts of polyglutamic acid, 8 parts of citric acid, 4 parts of calcium lactate, 11 parts of tween, 1 part of sorbitan trioleate and 6 parts of seaweed gel are respectively weighed according to the parts by weight of the components for later use;
in the second step, the pregnant mare urine extract prepared in the first step is poured into a dry powder stirrer, and the soybean isoflavone powder, the larch resin alcohol powder, the matairesinol powder, the arctigenin powder and the resveratrol glycoside powder prepared in the first step are added, stirred at 280r/min for 9min and uniformly mixed to obtain medicinal powder;
pouring the purified water prepared in the step one into a magnetic stirrer, adding the medicinal powder obtained in the step two, heating at 87 ℃, stirring and mixing uniformly at 100r/min, adding the polyglutamic acid, the citric acid and the calcium lactate prepared in the step one, heating, stirring and mixing uniformly to obtain a liquid medicine;
pouring the liquid medicine obtained in the third step into a rotary evaporator, adding the Tween, sorbitan trioleate and seaweed gel prepared in the first step, heating at 100 ℃, and rotating at a high speed of 140r/s to evaporate and discharge redundant water to obtain liquid medicine;
pouring the medicine slurry obtained in the fourth step into a granulator, and obtaining medicine granules with the discharged particle size of 50 meshes and the discharged water content of 1.8% after extrusion, rounding and drying;
and in the sixth step, the medicine granules obtained in the fifth step are poured into a tablet machine, the defatted coconut powder prepared in the first step is added, the mixture is pressed into tablets after mixing, tablet cores are obtained, then the tablets are transferred into a film coating machine, the surfaces of the tablet cores are coated with the prepared coating materials, and the tablets are taken out after being solidified into films, so that the biological medicine is obtained.
Example 3:
a biological agent suitable for female hormone supplementation comprises the following components: pregnant mare urine extract, soybean isoflavone powder, larch resin alcohol powder, matairesinol powder, arctigenin powder, resveratrol glycoside powder, defatted coconut powder, purified water, polyglutamic acid, citric acid, calcium lactate, tween, sorbitan trioleate and seaweed gel; the weight parts of the components are respectively as follows: 33 parts of pregnant mare urine extract, 12 parts of soybean isoflavone powder, 10 parts of larch resin alcohol powder, 10 parts of matairesinol powder, 4 parts of arctigenin powder, 4 parts of resveratrol glycoside powder, 73 parts of defatted coconut powder, 44 parts of purified water, 25 parts of polyglutamic acid, 9 parts of citric acid, 5 parts of calcium lactate, 11 parts of tween, 2 parts of sorbitan trioleate and 7 parts of seaweed gel.
A method for producing a biological agent suitable for supplementing hormones to women, comprising the steps of: step one, preparing materials; step two, stirring; step three, dissolving; step four, evaporating; step five, granulation; step six, tabletting;
in the first step, 33 parts of pregnant mare urine extract, 12 parts of soybean isoflavone powder, 10 parts of larch resin alcohol powder, 10 parts of palonodulcin powder, 4 parts of arctigenin powder, 4 parts of resveratrol glycoside powder, 73 parts of defatted coconut powder, 44 parts of purified water, 25 parts of polyglutamic acid, 9 parts of citric acid, 5 parts of calcium lactate, 11 parts of tween, 2 parts of sorbitan trioleate and 7 parts of seaweed gel are respectively weighed according to the parts by weight of the components for later use;
pouring the pregnant mare urine extract prepared in the step one into a dry powder stirrer, adding the soybean isoflavone powder, the larch resin alcohol powder, the matairesinol powder, the arctigenin powder and the resveratrol glycoside powder prepared in the step one, stirring at 280r/min for 9min, and uniformly mixing to obtain medicinal powder;
pouring the purified water prepared in the step one into a magnetic stirrer, adding the medicinal powder obtained in the step two, heating at 87 ℃, stirring and mixing uniformly at 100r/min, adding the polyglutamic acid, the citric acid and the calcium lactate prepared in the step one, heating, stirring and mixing uniformly to obtain a liquid medicine;
pouring the liquid medicine obtained in the third step into a rotary evaporator, adding the Tween, sorbitan trioleate and seaweed gel prepared in the first step, heating at 100 ℃, and rotating at a high speed of 140r/s to evaporate and discharge redundant water to obtain liquid medicine;
pouring the medicine slurry obtained in the fourth step into a granulator, and obtaining medicine granules with the discharged particle size of 50 meshes and the discharged water content of 1.8% after extrusion, rounding and drying;
and step six, pouring the medicine granules obtained in the step five into a tablet press, adding the defatted coconut powder prepared in the step one, mixing, pressing into tablets to obtain tablet cores, transferring the tablet cores into a film coating machine, coating the surfaces of the tablet cores with a prefabricated coating material, solidifying to form a film, and taking out to obtain the biological medicine.
Example 4:
a biological agent suitable for supplementing hormone for female comprises: pregnant mare urine extract, soybean isoflavone powder, larch resin alcohol powder, matairesinol powder, arctigenin powder, resveratrol glycoside powder, defatted coconut powder, purified water, polyglutamic acid, citric acid, calcium lactate, tween, sorbitan trioleate and seaweed gel; the weight parts of the components are respectively as follows: 37 parts of pregnant mare urine extract, 13 parts of soybean isoflavone powder, 11 parts of larch resin alcohol powder, 11 parts of matairesinol powder, 4 parts of arctigenin powder, 5 parts of resveratrol glycoside powder, 74 parts of defatted coconut powder, 46 parts of purified water, 26 parts of polyglutamic acid, 10 parts of citric acid, 5 parts of calcium lactate, 12 parts of tween, 2 parts of sorbitan trioleate and 8 parts of seaweed gel.
A method for producing a biological agent suitable for supplementing hormones to women, comprising the steps of: step one, preparing materials; step two, stirring; step three, dissolving; step four, evaporation; step five, granulation; step six, tabletting;
in the first step, 37 parts of pregnant mare urine extract, 13 parts of soybean isoflavone powder, 11 parts of larch resin powder, 11 parts of podocarpin powder, 4 parts of arctigenin powder, 5 parts of resveratrol glycoside powder, 74 parts of defatted coconut powder, 46 parts of purified water, 26 parts of polyglutamic acid, 10 parts of citric acid, 5 parts of calcium lactate, 12 parts of tween, 2 parts of sorbitan trioleate and 8 parts of seaweed gel are respectively weighed according to the weight parts of the components for later use;
in the second step, the pregnant mare urine extract prepared in the first step is poured into a dry powder stirrer, and the soybean isoflavone powder, the larch resin alcohol powder, the matairesinol powder, the arctigenin powder and the resveratrol glycoside powder prepared in the first step are added, stirred at 280r/min for 9min and uniformly mixed to obtain medicinal powder;
pouring the purified water prepared in the step one into a magnetic stirrer, adding the medicinal powder obtained in the step two, heating at 87 ℃, stirring and mixing uniformly at 100r/min, adding the polyglutamic acid, the citric acid and the calcium lactate prepared in the step one, heating, stirring and mixing uniformly to obtain a liquid medicine;
pouring the liquid medicine obtained in the third step into a rotary evaporator, adding the Tween, sorbitan trioleate and seaweed gel prepared in the first step, heating at 100 ℃, and rotating at a high speed of 140r/s to evaporate and discharge redundant water to obtain liquid medicine;
pouring the medicine slurry obtained in the fourth step into a granulator, and obtaining medicine granules with the discharged particle size of 50 meshes and the discharged water content of 1.8% after extrusion, rounding and drying;
and in the sixth step, the medicine granules obtained in the fifth step are poured into a tablet machine, the defatted coconut powder prepared in the first step is added, the mixture is pressed into tablets after mixing, tablet cores are obtained, then the tablets are transferred into a film coating machine, the surfaces of the tablet cores are coated with the prepared coating materials, and the tablets are taken out after being solidified into films, so that the biological medicine is obtained.
Example 5:
a biological agent suitable for female hormone supplementation comprises the following components: pregnant mare urine extract, soybean isoflavone powder, larch resin alcohol powder, matairesinol powder, arctigenin powder, resveratrol glycoside powder, defatted coconut powder, purified water, polyglutamic acid, citric acid, calcium lactate, tween, sorbitan trioleate and seaweed gel; the weight parts of the components are respectively as follows: 40 parts of pregnant mare urine extract, 14 parts of soybean isoflavone powder, 12 parts of larch resin alcohol powder, 12 parts of matairesinol powder, 5 parts of arctigenin powder, 5 parts of resveratrol glycoside powder, 76 parts of defatted coconut powder, 47 parts of purified water, 27 parts of polyglutamic acid, 11 parts of citric acid, 6 parts of calcium lactate, 12 parts of tween, 3 parts of sorbitan trioleate and 9 parts of seaweed gel.
A method for producing a biological agent suitable for supplementing hormones to women, comprising the steps of: step one, preparing materials; step two, stirring; step three, dissolving; step four, evaporation; step five, granulating; step six, tabletting;
in the first step, 40 parts of pregnant mare urine extract, 14 parts of soybean isoflavone powder, 12 parts of larch resin alcohol powder, 12 parts of matairesinol powder, 5 parts of arctigenin powder, 5 parts of resveratrol glycoside powder, 76 parts of defatted coconut powder, 47 parts of purified water, 27 parts of polyglutamic acid, 11 parts of citric acid, 6 parts of calcium lactate, 12 parts of tween, 3 parts of sorbitan trioleate and 9 parts of seaweed gel are respectively weighed according to the parts by weight of the components for later use;
in the second step, the pregnant mare urine extract prepared in the first step is poured into a dry powder stirrer, and the soybean isoflavone powder, the larch resin alcohol powder, the matairesinol powder, the arctigenin powder and the resveratrol glycoside powder prepared in the first step are added, stirred at 280r/min for 9min and uniformly mixed to obtain medicinal powder;
pouring the purified water prepared in the step one into a magnetic stirrer, adding the medicinal powder obtained in the step two, heating at 87 ℃, stirring and mixing uniformly at 100r/min, adding the polyglutamic acid, citric acid and calcium lactate prepared in the step one, heating, stirring and mixing uniformly to obtain a medicinal liquid;
pouring the liquid medicine obtained in the third step into a rotary evaporator, adding the Tween, sorbitan trioleate and seaweed gel prepared in the first step, heating at 100 ℃, and rotating at a high speed of 140r/s to evaporate and discharge redundant water to obtain liquid medicine;
pouring the medicine slurry obtained in the fourth step into a granulator, and obtaining medicine granules with the discharged particle size of 50 meshes and the discharged water content of 1.8% after extrusion, rounding and drying;
and in the sixth step, the medicine granules obtained in the fifth step are poured into a tablet machine, the defatted coconut powder prepared in the first step is added, the mixture is pressed into tablets after mixing, tablet cores are obtained, then the tablets are transferred into a film coating machine, the surfaces of the tablet cores are coated with the prepared coating materials, and the tablets are taken out after being solidified into films, so that the biological medicine is obtained.
The physical properties of the biological agents obtained in the above examples were tested and compared with the general chemical agents on the market, and the results are shown in the following table:
| 3h degradation/The% | 48h degradation/The% | |
| Example 1 | 71.23 | 96.08 |
| Example 2 | 71.59 | 96.35 |
| Example 3 | 71.62 | 96.89 |
| Example 4 | 72.05 | 97.11 |
| Example 5 | 72.27 | 97.33 |
| Comparative example | 40.15 | 68.42 |
Based on the above, the invention has the advantages that the biological substance is used as the main component, the dissolubility is strong, the degradation rate is high, the substance residue is less, the female health is ensured, the biological substance contains various phytoestrogens, the effective components are more, the hormone supplementing effect is good, the side effect is small, the adverse reaction is less, the applicability is strong, in addition, the dehydration degree during the production is increased through the rotary evaporation, the residual water in the medicament is less, the absorption of the effective components is ensured, and the curative effect is reliable.
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. Any reference sign in a claim should not be construed as limiting the claim concerned.
Claims (6)
1. A biological agent suitable for supplementing hormone for female comprises: pregnant mare urine extract, soybean isoflavone powder, larch resin alcohol powder, matairesinol powder, arctigenin powder, resveratrol glycoside powder, defatted coconut powder, purified water, polyglutamic acid, citric acid, calcium lactate, tween, sorbitan trioleate and seaweed gel; the method is characterized in that: the weight parts of the components are respectively as follows: 26-40 parts of pregnant mare urine extract, 10-14 parts of soybean isoflavone powder, 8-12 parts of larch resin alcohol powder, 8-12 parts of matairesinol powder, 3-5 parts of arctigenin powder, 3-5 parts of resveratrol glycoside powder, 70-76 parts of defatted coconut powder, 41-47 parts of purified water, 23-27 parts of polyglutamic acid, 7-11 parts of citric acid, 4-6 parts of calcium lactate, 10-12 parts of tween, 1-3 parts of sorbitan trioleate and 5-9 parts of seaweed gel.
2. A method for producing a biological agent suitable for supplementing hormones in women comprises the following steps: step one, preparing materials; step two, stirring; step three, dissolving; step four, evaporation; step five, granulating; step six, tabletting; the method is characterized in that:
in the first step, 26-40 parts of pregnant mare urine extract, 10-14 parts of soybean isoflavone powder, 8-12 parts of larch resin alcohol powder, 8-12 parts of matairesinol powder, 3-5 parts of arctigenin powder, 3-5 parts of resveratrol glycoside powder, 70-76 parts of defatted coconut powder, 41-47 parts of purified water, 23-27 parts of polyglutamic acid, 7-11 parts of citric acid, 4-6 parts of calcium lactate, 10-12 parts of tween, 1-3 parts of sorbitan trioleate and 5-9 parts of seaweed gel are weighed according to the parts by weight of the components for later use;
in the second step, the pregnant mare urine extract prepared in the first step is poured into a dry powder stirrer, and the soybean isoflavone powder, the larch resin alcohol powder, the matairesinol powder, the arctigenin powder and the resveratrol glycoside powder prepared in the first step are added, stirred and mixed uniformly to obtain medicinal powder;
pouring the purified water prepared in the step one into a magnetic stirrer, adding the medicinal powder obtained in the step two, heating, stirring and mixing uniformly, adding the polyglutamic acid, citric acid and calcium lactate prepared in the step one, heating, stirring and mixing uniformly to obtain a liquid medicine;
pouring the liquid medicine obtained in the third step into a rotary evaporator, adding the Tween, sorbitan trioleate and seaweed gel prepared in the first step, heating, rotating at a high speed, and evaporating and discharging redundant water to obtain liquid medicine;
pouring the medicine slurry obtained in the fourth step into a granulator, and obtaining medicine granules after extrusion, rounding and drying;
and in the sixth step, the medicine granules obtained in the fifth step are poured into a tablet machine, the defatted coconut powder prepared in the first step is added, the mixture is pressed into tablets after mixing, tablet cores are obtained, then the tablets are transferred into a film coating machine, the surfaces of the tablet cores are coated with the prepared coating materials, and the tablets are taken out after being solidified into films, so that the biological medicine is obtained.
3. The method for producing a female hormone replacement preparation according to claim 2, wherein the method comprises the steps of: in the second step, the stirring speed of the dry powder stirrer is 240-320 r/min, and the stirring time is 7-11 min.
4. The method for producing a female hormone replacement preparation according to claim 2, wherein the method comprises the steps of: in the third step, the heating temperature of the magnetic stirrer is 85-90 ℃, and the stirring speed is 80-120 r/min.
5. The method for producing a female hormone replacement preparation according to claim 2, wherein the method comprises the steps of: in the fourth step, the heating temperature of the rotary evaporator is 98-103 ℃, and the rotating speed is 120-150 r/s.
6. The method for producing a female hormone replacement preparation according to claim 2, wherein the method comprises the steps of: in the fifth step, the particle size of discharged materials of the granulator is 45-55 meshes, and the water content of the discharged materials is 1.6-1.9%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210829405.0A CN114984126A (en) | 2022-07-15 | 2022-07-15 | Biological agent suitable for supplementing hormone for female and production method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210829405.0A CN114984126A (en) | 2022-07-15 | 2022-07-15 | Biological agent suitable for supplementing hormone for female and production method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114984126A true CN114984126A (en) | 2022-09-02 |
Family
ID=83021799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210829405.0A Pending CN114984126A (en) | 2022-07-15 | 2022-07-15 | Biological agent suitable for supplementing hormone for female and production method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114984126A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001003687A2 (en) * | 1999-07-13 | 2001-01-18 | Cedars-Sinai Medical Center | Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans |
| CN1680240A (en) * | 2004-04-09 | 2005-10-12 | 汪云 | Composition containing resveratrol and soybean isoflavone and its preparation and use |
| CN101002814A (en) * | 2007-01-12 | 2007-07-25 | 苏州大学 | Medical use of burdock total lignanoid |
| US20080057140A1 (en) * | 2005-01-10 | 2008-03-06 | Mikko Unkila | Use of a Lignan for the Manufacture of a Composition for Preventing or Alleviating of Symptoms Relating to Estrogen Deficiency |
| CN103720720A (en) * | 2013-12-30 | 2014-04-16 | 新疆特丰药业股份有限公司 | Natural pregnant mare conjugated estrogen purification and refinement method and application of nonionic nonpolar fine separation resin used by same |
| CN111000819A (en) * | 2020-01-06 | 2020-04-14 | 一力制药股份有限公司 | Fukean film-coated tablet and preparation process thereof |
-
2022
- 2022-07-15 CN CN202210829405.0A patent/CN114984126A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001003687A2 (en) * | 1999-07-13 | 2001-01-18 | Cedars-Sinai Medical Center | Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans |
| CN1680240A (en) * | 2004-04-09 | 2005-10-12 | 汪云 | Composition containing resveratrol and soybean isoflavone and its preparation and use |
| US20080057140A1 (en) * | 2005-01-10 | 2008-03-06 | Mikko Unkila | Use of a Lignan for the Manufacture of a Composition for Preventing or Alleviating of Symptoms Relating to Estrogen Deficiency |
| CN101002814A (en) * | 2007-01-12 | 2007-07-25 | 苏州大学 | Medical use of burdock total lignanoid |
| CN103720720A (en) * | 2013-12-30 | 2014-04-16 | 新疆特丰药业股份有限公司 | Natural pregnant mare conjugated estrogen purification and refinement method and application of nonionic nonpolar fine separation resin used by same |
| CN111000819A (en) * | 2020-01-06 | 2020-04-14 | 一力制药股份有限公司 | Fukean film-coated tablet and preparation process thereof |
Non-Patent Citations (3)
| Title |
|---|
| 姚新奎等主编: "《马生产管理学》", 30 September 2008, 中国农业大学出版社 * |
| 王秀伶等: "膳食中的植物雌激素、肠道菌群与人类健康", 《世界华人消化杂志》 * |
| 邓舜扬主编: "《功能性食品与保健》", 31 August 2006, 科学技术文献出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104886554B (en) | Quick-fried pearl soft capsule and preparation method thereof | |
| CN101885853B (en) | Cured cross-linked glutinous rice flour hydrogel, preparation method and application thereof | |
| CN101401809B (en) | Preparation for composition of vitamin and mineral matter | |
| CN106265586A (en) | A kind of preparation method of calcitriol soft capsule preparation | |
| CN103463126A (en) | Calcium carbonate D3 granula and preparation method thereof | |
| CN107281218B (en) | High-absorption composite calcium supplement preparation and preparation method thereof | |
| CN104983732B (en) | A kind of cloth Lip river feritin that quick and preparation method thereof | |
| CN114984126A (en) | Biological agent suitable for supplementing hormone for female and production method thereof | |
| CN105535018A (en) | Calcium carbonate D3 granules and preparation method thereof | |
| CN102077955B (en) | Soluble konjac dietary fiber tablets and preparation method thereof | |
| CN110123770A (en) | A kind of Eliquis pharmaceutical composition and preparation method thereof | |
| CN106265581A (en) | A kind of tranexamic acid sheet and preparation method thereof | |
| CN104906060A (en) | Indapamide slow-release hypertension pill and preparation method thereof | |
| CN103565774A (en) | Glipizide controlled release composition as well as preparation method thereof | |
| CN103520232B (en) | A kind of preparation method of gel | |
| CN108853167A (en) | A kind of hemorrhoid composition containing chitosan, preparation method and applications | |
| CN101721388A (en) | micro-capsule containing vitamin d3 | |
| CN103877058A (en) | Levonorgestrel tablet and preparation process thereof | |
| CN111870587A (en) | Preparation method of film-coated premix added with beta-cyclodextrin | |
| CN102641247A (en) | Acid and alkali neutralization granulating method of effervescent | |
| CN105456205A (en) | Preparing process of enrofloxacin slow release granula | |
| CN103784472B (en) | A kind of calcium preparation and its production and use | |
| CN104224749B (en) | A kind of novel non-gelatin soft capsule and preparation method thereof | |
| CN102441286B (en) | Method for improving melt wall sticking during spray drying of traditional Chinese medicine or food raw material | |
| CN101224199B (en) | Anetholtnithoines and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220902 |
|
| RJ01 | Rejection of invention patent application after publication |